Since CTC enriching and counting was performed from two parallel blood draws, the between-assay variability was firstly evaluated using clinical in-house data collected from 22 Metastatic Breast Cancer (MBC) patients, tested for M30 and HER2 expression in CTCs. This evidence concerns the gene ERBB2 and breast carcinoma.